Diazyme Laboratories, Inc.

Home
United States
Poway, CA
Diazyme Laboratories, Inc.

Diazyme is a clinical chemistry reagent manufacturer that develops IVD assays for use on conventional open channel automated chemistry platforms.

04/28/2026

The future of biomarker diagnostics: Diazyme’s commitment to advancing lab medicine.

At Diazyme, we’re focused on shaping the future of biomarker diagnostics with cutting-edge solutions that help healthcare providers detect, diagnose, and manage diseases more effectively. Our commitment to innovation is driving the development of next-generation assays that enhance accuracy, streamline workflows, and improve patient outcomes.

As we look ahead, we remain dedicated to advancing lab medicine and providing the tools necessary for better, more proactive healthcare.

The future of diagnostics is here—and we’re proud to be at the forefront of it.

Discover how we’re driving lab innovation: https://bit.ly/36lKaaV

04/22/2026

The Diazyme Total Bile Acids Assay provides laboratories with a reliable and efficient solution for quantitative bile acid measurement in serum. With liquid stable reagents and results in as little as 8 minutes, laboratories can streamline testing while maintaining dependable performance.

Key advantages include:
✔ Minimal interference from triglycerides, bilirubin, and hemolysis
✔ Results in as little as 8 minutes
✔ Liquid stable reagents
✔ Flexible instrument parameters to support simplified implementation

Learn more about the assay and how it supports clinical laboratories:
🔗 https://bit.ly/4lRG3Ko

04/19/2026

Supporting Liver Health on World Liver Day

The liver plays a vital role in overall health, yet liver diseases often go undiagnosed until they reach advanced stages. At Diazyme, we’re committed to improving liver health diagnostics with innovative assays like the Total Bile Acid (TBA) assay and Adenosine Deaminase (ADA) assay, which are critical for the early detection and monitoring of liver function.

These advanced solutions equip healthcare professionals with the tools they need for accurate diagnoses and better patient outcomes.

This World Liver Day, let’s raise awareness about the importance of liver health and the role of diagnostics in prevention and early intervention.

Take a closer look at our complete Liver Health Panel: https://bit.ly/3N2sBms

04/14/2026

Closing the Gap in Diabetes Monitoring 🩺

Effective diabetes management requires more than just a single snapshot of blood sugar levels. By combining multiple diagnostic assays, clinicians can gain a comprehensive view of a patient’s glycemic control—both short-term and long-term.

🩸 Key Assays Working Well Together:
✅ HbA1c: Tracks average blood glucose over the past 2–3 months for long-term trends.
✅ 1,5-AG (1,5-Anhydroglucitol): Highlights short-term glycemic spikes and recent glucose variability.
✅ GSP (Glycated Serum Protein): Offers insights into glucose patterns over the past 2–3 weeks.

🔬 Why Combine These Assays?
Together, they provide a clearer picture of glycemic patterns, help identify risks, and guide personalized care strategies.

💡 Closing the gap in diabetes monitoring means having the full picture—one that empowers better decisions, earlier interventions, and improved outcomes.

View all Diabetic Markers - https://bit.ly/3A6C7SA

04/09/2026

Supporting Better Diabetes Management with Advanced Testing

Effective diabetes management starts with accurate monitoring. Diazyme’s Diabetic Markers Panel includes advanced HbA1c, Glycated Serum Protein (GSP), and 1,5-AG assays, providing a comprehensive view of both long-term and short-term glucose control. These markers give healthcare providers the insights they need to optimize patient care and improve outcomes.

With innovative diagnostics, we’re making early detection and proactive diabetes care more accessible. Learn more about how our solutions support better health management.

Learn More about our Diabetic Markers: https://bit.ly/3A6C7SA

#1,5AG

04/08/2026

New ESC/EAS Guidelines on Lp(a)

Recent ESC/EAS guidance highlights the growing importance of lipoprotein(a) in cardiovascular risk assessment.

Key takeaways:
✅ Lp(a) is recognized as a risk-enhancing factor
✅ Measurement is recommended at least once in all adults
✅ Elevated levels can help identify hidden cardiovascular risk
✅ Supports more informed risk stratification and management decisions

As clinical guidelines continue to evolve, incorporating Lp(a) testing into routine evaluation is becoming increasingly important for early risk identification.

Diazyme’s Lp(a) assay supports laboratories with fast, reliable measurement and efficient workflow integration.

Learn more about Diazyme’s Lp(a) assay:
➡️https://www.diazyme.com/cardiovascular-markers/liprotein-lp-a-assay/

Read more on the new guidance:
➡️https://www.hcplive.com/view/lipid-management-in-special-populations-from-2026-dyslipidemia-guidelines

➡️https://www.patientcareonline.com/view/new-dyslipidemia-guidelines-emphasize-ldl-c-targets-lp-screening-pcps

04/06/2026

Spotlight on Gastro Health Panel: Supporting GI Health

Gastrointestinal disorders can significantly impact a patient’s quality of life, and assessing key biomarkers can help guide effective management. Diazyme’s Gastro Health Panel provides essential markers that support healthcare providers in evaluating gut health and making informed decisions for patient care.

By delivering reliable and efficient testing solutions, we’re helping to advance proactive approaches to digestive health.

Let’s emphasize the importance of gut health and proactive care this month!

04/01/2026

Irritable Bowel Syndrome (IBS) affects millions worldwide and diagnosing it can be a challenge. While no single test can diagnose IBS, Diazyme’s Gastro Health Panel can provide valuable insights into key gastrointestinal markers that help healthcare providers assess overall gut health.

By offering reliable and efficient testing solutions, we support healthcare providers in improving patient care.

Let’s raise awareness for IBS and the importance of gut health this month!

Start Prioritizing Gut Health Today: https://bit.ly/3YjCvVE

03/30/2026

Join the Diazyme Team

Be part of a team driven by innovation, collaboration, and a shared commitment to advancing diagnostic solutions.

Explore opportunities to grow your career and make an impact with Diazyme.

Explore our Career page ➡️ https://bit.ly/4stQ0j8

03/24/2026

Through American Diabetes Alert Day, we aim to raise awareness and work towards better methods of monitoring this global health challenge.

Diabetes is a metabolic disease that elevates blood sugar levels, leading to severe medical complications and causing millions of premature deaths each year. It has now become one of the leading causes of death worldwide.

At Diazyme, our expansive assay menu includes a unique collection of Diabetic Markers designed to equip clinical laboratories with the tools they need to better monitor and diagnose diabetic patients.

Explore our Diabetic Markers: https://bit.ly/3A6C7SA

03/19/2026

March is National Kidney Month, and at Diazyme Laboratories, we're proud to highlight the importance of renal markers in advancing kidney health!

Through our cutting-edge assays such as Enzymatic Creatinine and Cystatin C, we're dedicated to providing accurate and reliable testing options that empower healthcare professionals to monitor kidney health with precision and confidence.

Our comprehensive portfolio of renal markers enables clinicians to make informed decisions and tailor treatment strategies for patients with kidney-related conditions.

Join Diazyme Laboratories in recognizing National Kidney Month and advocating for kidney health!

Read More about our Renal and Pancreatic Markers Here:
https://bit.ly/4ioAmRa

03/16/2026

Why Monitor Kappa & Lambda Free Light Chains?

Normally, there's a balance between kappa and lambda free light chains in the bloodstream. However, in certain diseases, particularly plasma cell disorders such as multiple myeloma, there can be an imbalance in the production of these free light chains. This imbalance can lead to an excess of one type of light chain over the other, which is known as a kappa-lambda ratio imbalance.

This imbalance can be detected through laboratory tests, such as Diazyme’s Kappa and Lambda serum free light chain assays, which measures the levels of kappa and lambda free light chains in the blood. Monitoring the kappa-lambda ratio is important in the diagnosis and management of plasma cell disorders.

Learn More about these assays and to support healthcare providers in assessing disease progression and response to treatment.
https://bit.ly/4h7z6kn

Address

12889 Gregg Court
Poway, CA
92064

Website

http://www.diazyme.com/

Alerts

Be the first to know and let us send you an email when Diazyme Laboratories, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed Clinic in Poway?